Login Register Cart 0
Generic placeholder image

Current Nanomedicine

Editor-in-Chief

ISSN (Print): 2468-1873
ISSN (Online): 2468-1881

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

The Emerging Role of Nanosuspensions for Drug Delivery and Stability

Author(s): Hitesh Kumar Dewangan*

Volume 11, Issue 4, 2021

Published on: 27 December, 2021

Page: [213 - 223] Pages: 11

DOI: 10.2174/2468187312666211222123307

Price: $65

Abstract

Poor solubility of some medicinal compounds is a serious challenge that can be addressed by using a nano-suspension for improved delivery. The nanoparticles enhance the bioavailability along with the aqueous solubility of the drug, which is accomplished by increasing the active surface area of the drug. The gained attention of the nanosuspension is due to its stabilization facility, which is achieved by polymers, such as polyethylene glycol (PEG), having a particular size range of 10 - 100 nm. Hence, these nanoparticles have the capacity of binding to the targeted with very low damage to the healthy tissues. These are prepared by various methods, such as milling, high-pressure homogenization, and emulsification, along with melt emulsification. Moreover, surface modification and solidification have been used to add specific properties to the advanced therapies as post-processing techniques. For many decades, it has been known that water solubility hampers the bioavailability and not all drugs are water-soluble. In order to combat this obstacle, nanotechnology has been found to be of specific interest. For elevating the bioavailability by increasing the dissolution rate, the methodology of reduction of the associated drug particles into their subsequent submicron range is incorporated. For oral and non-oral administration, these nanosuspension formulations are used for the delivery of drugs.

Keywords: Nano-suspension, drug delivery, bioavailability, cell membrane, medicinal compounds, nanoparticles.

« Previous Next »
Graphical Abstract

[1]
Chen H, Khemtong C, Yang X, Chang X, Gao J. Nanonization strategies for poorly water-soluble drugs. Drug Discov Today 2011; 16(7-8): 354-60.
[http://dx.doi.org/10.1016/j.drudis.2010.02.009] [PMID: 20206289]
[2]
Patel VR, Agrawal YK. Nanosuspension: An approach to enhance solubility of drugs. J Adv Pharm Technol Res 2011; 2(2): 81-7.
[http://dx.doi.org/10.4103/2231-4040.82950] [PMID: 22171298]
[3]
Mercadante S, Vitrano V. Pain in patients with lung cancer: Pathophysiology and treatment. Lung Cancer 2010; 68(1): 10-5.
[http://dx.doi.org/10.1016/j.lungcan.2009.11.004] [PMID: 20007003]
[4]
Bergström CAS, Wassvik CM, Johansson K, Hubatsch I. Poorly soluble marketed drugs display solvation limited solubility. J Med Chem 2007; 50(23): 5858-62.
[http://dx.doi.org/10.1021/jm0706416] [PMID: 17929794]
[5]
Bhal SK, Kassam K, Peirson IG, Pearl GM. The rule of five revisited: Applying log D in place of log P in drug-likeness filters. Mol Pharm 2007; 4(4): 556-60.
[http://dx.doi.org/10.1021/mp0700209] [PMID: 17530776]
[6]
Wassvik CM, Holmén AG, Draheim R, Artursson P, Bergström CAS. Molecular characteristics for solid-state limited solubility. J Med Chem 2008; 51(10): 3035-9.
[http://dx.doi.org/10.1021/jm701587d] [PMID: 18396854]
[7]
Kamal P, Kumari B. Versatility of nanosuspension formulation in various drug delivery systems: A brief review. Adv Pharm J 2020; 5(2): 36-46.
[http://dx.doi.org/10.31024/apj.2020.5.2.1]
[8]
Nayak AK, Panigrahi PP. Solubility enhancement of etoricoxib by cosolvency approach. ISRN Phys Chem 2012; 21: 1-5.
[http://dx.doi.org/10.5402/2012/820653]
[9]
Nippe S, General S. Parenteral oil-based drospirenone microcrystal suspensions-evaluation of physicochemical stability and influence of stabilising agents. Int J Pharm 2011; 416(1): 181-8.
[http://dx.doi.org/10.1016/j.ijpharm.2011.06.036] [PMID: 21729745]
[10]
Lakshmi AP, Kumar MA, Krishna MV, Vijetha KA, Ashwini G. Formulation development of irbesartan (poorly water-soluble drug) immediate release tablets. Int Res J Pharm 2012; 3: 117-20.
[11]
Arias MJ, Moyano JR, Gines JM. Investigation of the triamterene-β-cyclodextrin system prepared by co-grinding. Int J Pharm 1997; 153(2): 181-9.
[http://dx.doi.org/10.1016/S0378-5173(97)00101-4] [PMID: 10477815]
[12]
Rogers TL, Nelsen AC, Hu J, et al. A novel particle engineering technology to enhance dissolution of poorly water soluble drugs: Spray-freezing into liquid. Eur J Pharm Biopharm 2002; 54(3): 271-80.
[http://dx.doi.org/10.1016/S0939-6411(02)00063-2] [PMID: 12445556]
[13]
Ventura CA, Tirendi S, Puglisi G, Bousquet E, Panza L. Improvement of water solubility and dissolution rate of ursodeoxycholic acid and chenodeoxycholic acid by complexation with natural and modified β-cyclodextrins. Int J Pharm 1997; 149(1): 1-13.
[http://dx.doi.org/10.1016/S0378-5173(96)04821-1]
[14]
Floyd AG. Top ten considerations in the development of parenteral emulsions. Pharm Sci Technol Today 1999; 4(2): 134-43.
[http://dx.doi.org/10.1016/S1461-5347(99)00141-8] [PMID: 10322370]
[15]
Nakano M. Places of emulsions in drug delivery. Adv Drug Deliv Rev 2000; 45(1): 1-4.
[http://dx.doi.org/10.1016/S0169-409X(00)00096-X] [PMID: 11104893]
[16]
Lawrence MJ, Rees GD. Microemulsion-based media as novel drug delivery systems. Adv Drug Deliv Rev 2000; 45(1): 89-121.
[http://dx.doi.org/10.1016/S0169-409X(00)00103-4] [PMID: 11104900]
[17]
Oliveira MP, de-Garcion E, Venisse N, Benoıt JP, Couet W, Olivier JC. Tissue distribution of indinavir administered mdr1a (−/−) CF-1 mice. Pharm Res 2005; 22(11): 1898-905.
[http://dx.doi.org/10.1007/s11095-005-7147-6] [PMID: 16132350]
[18]
Moneghini M, Kikic I, Voinovich D, Perissutti B, Filipović-Grcić J. Processing of carbamazepine-PEG 4000 solid dispersions with supercritical carbon dioxide: Preparation, characterisation, and in vitro dissolution. Int J Pharm 2001; 222(1): 129-38.
[http://dx.doi.org/10.1016/S0378-5173(01)00711-6] [PMID: 11404039]
[19]
Zerrouk N, Chemtob C, Arnaud P, Toscani S, Dugue J. In vitro and in vivo evaluation of carbamazepine-PEG 6000 solid dispersions. Int J Pharm 2001; 225(1-2): 49-62.
[http://dx.doi.org/10.1016/S0378-5173(01)00741-4] [PMID: 11489554]
[20]
Rao GCS, Kumar MS, Mathivanan N, Rao MEB. Nanosuspensions as the most promising approach in nanoparticulate drug delivery systems. Pharmazie 2004; 59(1): 5-9.
[PMID: 14964413]
[21]
Muller RH. Nanosuspension for the i.v. administration of poorly soluble drugs—stability during sterilization and long-term storage. Proceedings of the 22nd International Symposium on Controlled Release of Bioactive Materials, 1995, Controlled Release Society. 574-5.
[22]
Muller RH, Becker R, Kruss B, Peters K. Pharmaceutical nanosuspensions for medicament administration as system of increased saturation solubility and rate of solution. US Patent, US5858410A, 1999.
[23]
Dewangan HK, Pandey T, Singh S. Nanovaccine for immunotherapy and reduced hepatitis-B virus in humanized model. Artificial Cell Nanomed Biotech 2018; 46(8)
[http://dx.doi.org/10.1080/21691401.2017.1408118] [PMID: 29179600]
[24]
Ayash N. Review on preparation, characterization, and pharmaceutical application of nanosuspension as an approach of solubility and dissolution enhancement. J Pharm Res 2018; 12(5): 771-4.
[25]
Sanganwar GP, Sathigari S, Babu RJ, Gupta RB. Simultaneous production and co-mixing of microparticles of nevirapine with excipients by supercritical antisolvent method for dissolution enhancement. Eur J Pharm Sci 2010; 39(1-3): 164-74.
[http://dx.doi.org/10.1016/j.ejps.2009.11.011] [PMID: 19961931]
[26]
Chingunpituk J. Nanosuspension technology for drug delivery. Walailak J Sci Technol 2007; 4(2): 139-53.
[27]
Blanco E, Kessinger CW, Sumer BD, Gao J. Multifunctional micellar nanomedicine for cancer therapy. Exp Biol Med (Maywood) 2009; 234(2): 123-31.
[http://dx.doi.org/10.3181/0808-MR-250] [PMID: 19064945]
[28]
Freitas RA Jr. What is nanomedicine? Nanomedicine 2005; 1(1): 2-9.
[http://dx.doi.org/10.1016/j.nano.2004.11.003] [PMID: 17292052]
[29]
Morrow KJ Jr, Bawa R, Wei C. Recent advances in basic and clinical nanomedicine. Med Clin North Am 2007; 91(5): 805-43.
[http://dx.doi.org/10.1016/j.mcna.2007.05.009] [PMID: 17826104]
[30]
Chan VS. Nanomedicine: An unresolved regulatory issue. Regul Toxicol Pharmacol 2006; 46(3): 218-24.
[http://dx.doi.org/10.1016/j.yrtph.2006.04.009] [PMID: 17081666]
[31]
Prabhakar C, Krishna KB. A review on nanosuspensions in drug delivery. Int J Pharma Bio Sci 2011; 2(1): 549-58.
[32]
Nagelreiter C, Valenta C. Size analysis of nanoparticles in commercial O/W sunscreens. Int J Pharm 2013; 456(2): 517-9.
[http://dx.doi.org/10.1016/j.ijpharm.2013.08.024] [PMID: 23994364]
[33]
Ojewole E, Mackraj I, Naidoo P, Govender T. Exploring the use of novel drug delivery systems for antiretroviral drugs. Eur J Pharm Biopharm 2008; 70(3): 697-710.
[http://dx.doi.org/10.1016/j.ejpb.2008.06.020] [PMID: 18655830]
[34]
Müller RH, Keck CM. Twenty years of drug nanocrystals: Where are we, and where do we go? Eur J Pharm Biopharm 2012; 80(1): 1-3.
[http://dx.doi.org/10.1016/j.ejpb.2011.09.012] [PMID: 21971369]
[35]
Merisko-Liversidge E, Liversidge GG, Cooper ER. Nanosizing: A formulation approach for poorly-water-soluble compounds. Eur J Pharm Sci 2003; 18(2): 113-20.
[http://dx.doi.org/10.1016/S0928-0987(02)00251-8] [PMID: 12594003]
[36]
Hou CD, Wang JX, Le Y, Zou HK, Zhao H. Preparation of azithromycin nanosuspensions by reactive precipitation method. Drug Dev Ind Pharm 2012; 38(7): 848-54.
[http://dx.doi.org/10.3109/03639045.2011.630394] [PMID: 22092042]
[37]
Hill A, Geissler S, Weigandt M, Mäder K. Controlled delivery of nanosuspensions from osmotic pumps: Zero order and non-zero order kinetics. J Control Release 2012; 158(3): 403-12.
[http://dx.doi.org/10.1016/j.jconrel.2011.12.005] [PMID: 22198270]
[38]
Wang Y, Zhang D, Liu Z, et al. In vitro and in vivo evaluation of silybin nanosuspensions for oral and intravenous delivery. Nanotechnology 2010; 21(15): 155104-12.
[http://dx.doi.org/10.1088/0957-4484/21/15/155104] [PMID: 20332565]
[39]
Sharma V, Dewangan HK, Mourya L, Vats K, Verma H, Singh S. Rational design and in-vivo estimation of Ivabradine Hydrochloride loaded nanoparticles for management of stable angina. J Drug Deliv Sci Technol 2019; 54: 101337-46.
[http://dx.doi.org/10.1016/j.jddst.2019.101337]
[40]
Pandya VM, Patel JK, Patel DJ. Formulation, optimization and characterization of simvastatin nanosuspension prepared by nanoprecipitation technique. Pharm Lett 2011; 3: 129-40.
[41]
Nakarani M, Misra AK, Patel JK, Vaghani SS. Itraconazole nanosuspension for oral delivery: Formulation, characterization and in vitro comparison with marketed formulation. Daru 2010; 18(2): 84-90.
[PMID: 22615599]
[42]
Peters K, Leitzke S, Diederichs JE, et al. Preparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine Mycobacterium avium infection. J Antimicrob Chemother 2000; 45(1): 77-83.
[http://dx.doi.org/10.1093/jac/45.1.77] [PMID: 10629016]
[43]
Mourya L, Vijaykumar MR, Dewangan HK, Singh S. Lipid based Aqueous Core Nanocapsules (ACNs) for encapsulating hydrophillic vinorelbine bitartrate: Preparation, optimization, characterization and in vitro safety assessment for intravenous administration. Curr Drug Del 2018; 15(9): 1284-93.
[44]
Kakran M, Shegokar R, Sahoo NG, Shaal LA, Li L, Müller RH. Fabrication of quercetin nanocrystals: Comparison of different methods. Eur J Pharm Biopharm 2012; 80(1): 113-21.
[http://dx.doi.org/10.1016/j.ejpb.2011.08.006] [PMID: 21896330]
[45]
Zhang J, Lv H, Jiang K, Gao Y. Enhanced bioavailability after oral and pulmonary administration of baicalein nanocrystal. Int J Pharm 2011; 420(1): 180-8.
[http://dx.doi.org/10.1016/j.ijpharm.2011.08.023] [PMID: 21878378]
[46]
Xiong R, Lu W, Yue P, et al. Distribution of an intravenous injectable nimodipine nanosuspension in mice. J Pharm Pharmacol 2008; 60(9): 1155-9.
[http://dx.doi.org/10.1211/jpp.60.9.0006] [PMID: 18718118]
[47]
Deepika D, Dewangan HK, Maurya L, Singh S. Intranasal drug delivery of frovatriptan succinate-loaded polymeric nanoparticles for brain targeting. J Pharm Sci 2019; 108(2): 851-9.
[http://dx.doi.org/10.1016/j.xphs.2018.07.013] [PMID: 30053555]
[48]
Shegokar R, Jansch M, Singh KK, Müller RH. In vitro protein adsorption studies on nevirapine nanosuspensions for HIV/AIDS chemotherapy. Nanomedicine 2011; 7(3): 333-40.
[http://dx.doi.org/10.1016/j.nano.2010.10.012] [PMID: 21094278]
[49]
Gao L, Zhang D, Chen M, et al. Studies on pharmacokinetics and tissue distribution of oridonin nanosuspensions. Int J Pharm 2008; 355(1-2): 321-7.
[http://dx.doi.org/10.1016/j.ijpharm.2007.12.016] [PMID: 18242896]
[50]
Bucolo C, Maltese A, Puglisi G, Pignatello R. Enhanced ocular anti-inflammatory activity of ibuprofen carried by an Eudragit RS100 nanoparticle suspension. Ophthalmic Res 2002; 34(5): 319-23.
[http://dx.doi.org/10.1159/000065608] [PMID: 12381895]
[51]
Dandagi P, Kerur S, Mastiholimath V, Gadad A, Kulkarni A. Polymeric ocular nanosuspension for controlled release of acyclovir: in vitro release and ocular distribution. Iran J Pharm Res 2010; 79-86.
[52]
Chiang PC, Hu Y, Thurston A, et al. Pharmacokinetic and pharmacodynamic evaluation of the suitability of using fluticasone and an acute rat lung inflammation model to differentiate lung versus systemic efficacy. J Pharm Sci 2009; 98(11): 4354-64.
[http://dx.doi.org/10.1002/jps.21714] [PMID: 19230021]
[53]
Tam JM, Engstrom JD, Ferrer D, Williams RO III, Johnston KP. Templated open flocs of anisotropic particles for pulmonary delivery with pressurized metered dose inhalers. J Pharm Sci 2010; 99(7): 3150-65.
[http://dx.doi.org/10.1002/jps.22091] [PMID: 20187139]
[54]
Dewangan HK, Singh S, Maurya L, Srivastava A, Hepatitis B, Hepatitis B. Hepatitis B antigen loaded biodegradable polymeric nanoparticles: Formulation optimization and in-vivo immunization in BALB/c mice. Curr Drug Deliv 2018; 15(8): 1204-15.
[http://dx.doi.org/10.2174/1567201815666180604110457] [PMID: 29866006]
[55]
Bourezg Z, Bourgeois S, Pressenda S, Shehada T, Fessi H. Redispersible lipid nanoparticles of Spironolactone obtained by three drying methods. Colloids Surf A Physicochem Eng Asp 2012; 413(5): 191-9.
[http://dx.doi.org/10.1016/j.colsurfa.2012.03.027]
[56]
Wang Y, Zheng Y, Zhang L, Wang Q, Zhang D. Stability of nanosuspensions in drug delivery. J Control Release 2013; 172(3): 1126-41.
[http://dx.doi.org/10.1016/j.jconrel.2013.08.006] [PMID: 23954372]
[57]
Müller RH, Jacobs C. Buparvaquone mucoadhesive nanosuspension: Preparation, optimisation and long-term stability. Int J Pharm 2002; 237(1-2): 151-61.
[http://dx.doi.org/10.1016/S0378-5173(02)00040-6] [PMID: 11955813]
[58]
Beirowski J, Inghelbrecht S, Arien A, Gieseler H. Freeze-drying of nanosuspensions, part 3: Investigation of factors compromising storage stability of highly concentrated drug nanosuspensions. J Pharm Sci 2012; 101(1): 354-62.
[http://dx.doi.org/10.1002/jps.22745] [PMID: 21905035]
[59]
Malamatari M, Somavarapu S, Taylor KM, Buckton G. Solidification of nanosuspensions for the production of solid oral dosage forms and inhalable dry powders. Expert Opin Drug Deliv 2016; 13(3): 435-50.
[http://dx.doi.org/10.1517/17425247.2016.1142524] [PMID: 26764574]
[60]
Singh AV, Maharjan RS, Kromer C, et al. Advances in smoking related in vitro inhalation toxicology: A perspective case of challenges and opportunities from progresses in lung-on-chip technologies. Chem Res Toxicol 2021; 34(9): 1984-2002.
[http://dx.doi.org/10.1021/acs.chemrestox.1c00219] [PMID: 34397218]
[61]
Singh AV, Romeo A, Scott A, et al. Emerging technologies for in vitro inhalation toxicology. Adv Healthcare Mater 2021; 10(18): 2100633.
[http://dx.doi.org/10.1002/adhm.202100633]
[62]
Jacobs C, Müller RH. Production and characterization of a budesonide nanosuspension for pulmonary administration. Pharm Res 2002; 19(2): 189-94.
[http://dx.doi.org/10.1023/A:1014276917363] [PMID: 11883646]
[63]
Niwa T, Miura S, Danjo K. Design of dry nanosuspension with highly spontaneous dispersible characteristics to develop solubilized formulation for poorly water-soluble drugs. Pharm Res 2011; 28(9): 2339-49.
[http://dx.doi.org/10.1007/s11095-011-0465-y] [PMID: 21626059]
[64]
Rabinow BE. Nanosuspensions for parenteral delivery. In: Nanoparticulate Drug Delivery Systems. London, UK: Informa Healthcare 2007; pp. 33-9.
[65]
Liversidge GG, Cundy KC. Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: Absolute oral bioavailability of nanocrystalline danazol in beagle dogs. Int J Pharm 1995; 125: 91-7.
[http://dx.doi.org/10.1016/0378-5173(95)00122-Y]
[66]
Behzadi S, Serpooshan V, Tao W, et al. Cellular uptake of nanoparticles: Journey inside the cell. Chem Soc Rev 2017; 46(14): 4218-44.
[http://dx.doi.org/10.1039/C6CS00636A] [PMID: 28585944]
[67]
Pu X, Sun J, Li M, He Z. Formulation of nanosuspensions as a new approach for the delivery of poorly soluble drugs. Curr Nanosci 2009; 5: 417-27.
[http://dx.doi.org/10.2174/157341309789378177]
[68]
Reddy GA, Chowdary AY. Nanosuspension technology: A review. J Pharm Cosmetol 2012; 2(8): 47-52.
[69]
Sylvestre JP, Tang MC, Furtos A, Leclair G, Meunier M, Leroux JC. Nanonization of megestrol acetate by laser fragmentation in aqueous milieu. J Control Release 2011; 149(3): 273-80.
[http://dx.doi.org/10.1016/j.jconrel.2010.10.034] [PMID: 21047539]
[70]
McMillan J, Batrakova E, Gendelman HE. Cell delivery of therapeutic nanoparticles. Prog Mol Biol Transl Sci 2011; 104: 563-601.
[http://dx.doi.org/10.1016/B978-0-12-416020-0.00014-0] [PMID: 22093229]
[71]
Dewangan HK, Pandey T, Maurya L, Singh S. Rational design and evaluation of HBsAg polymeric nanoparticles as antigen delivery carriers. Int J Biol Macromol 2018; 111: 804-12.
[http://dx.doi.org/10.1016/j.ijbiomac.2018.01.073] [PMID: 29343454]
[72]
Constantinides PP, Chaubal MV, Shorr R. Advances in lipid nanodispersions for parenteral drug delivery and targeting. Adv Drug Deliv Rev 2008; 60(6): 757-67.
[http://dx.doi.org/10.1016/j.addr.2007.10.013] [PMID: 18096269]
[73]
Barret ER, Press CRC, Boca R. Nanosuspension for parenteral delivery. In: Nanoparticulate Drug Delivery Systems. London, UK: Informa Healthcare 2007; pp. 166-78.
[74]
Daebis N, Ossama Y. Abdallah, EI- Massik M, Abdelkader H. Formulation and characterization of nanosuspension of Iraconozole oral Methyl cellulose as promising stabilizer. Elyns J Pharma Res 2015; 1(1): 102-15.
[75]
Rowe RC, Sheskey PJ, Quinn M. Handbook of pharmaceutical excipients. London: Pharmaceutical Press 2013; 7: pp. 544-51.
[76]
Frank KJ, Boeck G. Development of a nanosuspension for iv administration: From miniscale screening to a freeze dried formulation. Eur J Pharm Sci 2016; 87: 112-7.
[http://dx.doi.org/10.1016/j.ejps.2016.03.003] [PMID: 26970283]
[77]
Valo HK, Laaksonen PH, Peltonen LJ, Linder MB, Hirvonen JT, Laaksonen TJ. Multifunctional hydrophobin: Toward functional coatings for drug nanoparticles. ACS Nano 2010; 4(3): 1750-8.
[http://dx.doi.org/10.1021/nn9017558] [PMID: 20210303]
[78]
Ndong Ntoutoume GMA, Granet R, Mbakidi JP, et al. Development of curcumin-cyclodextrin/cellulose nanocrystals complexes: New anticancer drug delivery systems. Bioorg Med Chem Lett 2016; 26(3): 941-5.
[http://dx.doi.org/10.1016/j.bmcl.2015.12.060] [PMID: 26739777]
[79]
Liu Y, Huang L, Liu F. Paclitaxel nanocrystals for overcoming multidrug resistance in cancer. Mol Pharm 2010; 7(3): 863-9.
[http://dx.doi.org/10.1021/mp100012s] [PMID: 20420443]
[80]
Shang L, Nienhaus K, Nienhaus GU. Engineered nanoparticles interacting with cells: Size matters. J Nanobiotechnol 2014; 12: 5.
[http://dx.doi.org/10.1186/1477-3155-12-5] [PMID: 24491160]
[81]
Wang T, Bai J, Jiang X, Nienhaus GU. Cellular uptake of nanoparticles by membrane penetration: A study combining confocal microscopy with FTIR spectroelectrochemistry. ACS Nano 2012; 6(2): 1251-9.
[http://dx.doi.org/10.1021/nn203892h] [PMID: 22250809]
[82]
Kuhn DA, Vanhecke D, Michen B, et al. Different endocytotic uptake mechanisms for nanoparticles in epithelial cells and macrophages. Beilstein J Nanotechnol 2014; 5: 1625-36.
[http://dx.doi.org/10.3762/bjnano.5.174] [PMID: 25383275]
[83]
Treuel L, Jiang X, Nienhaus GU. New views on cellular uptake and trafficking of manufactured nanoparticles. J R Soc Interface 2013; 10(82): 20120939.
[http://dx.doi.org/10.1098/rsif.2012.0939]
[84]
Garg A, Dewangan HK. Nanoparticles as adjuvants in vaccine delivery. Crit Rev Ther Drug Carrier Syst 2020; 37(2): 183-204.
[http://dx.doi.org/10.1615/CritRevTherDrugCarrierSyst.2020033273] [PMID: 32865905]
[85]
dos Santos T, Varela J, Lynch I, Salvati A, Dawson KA. Effects of transport inhibitors on the cellular uptake of carboxylated polystyrene nanoparticles in different cell lines. PLoS One 2011; 6(9): e24438.
[http://dx.doi.org/10.1371/journal.pone.0024438] [PMID: 21949717]
[86]
Jiang L, Li X, Liu L, Zhang Q. Cellular uptake mechanism and intracellular fate of hydrophobically modified pullulan nanoparticles. Int J Nanomedicine 2013; 8: 1825-34.
[PMID: 23674894]
[87]
Garaiova Z, Strand SP, Reitan NK, et al. Cellular uptake of DNA-chitosan nanoparticles: The role of clathrin- and caveolae-mediated pathways. Int J Biol Macromol 2012; 51(5): 1043-51.
[http://dx.doi.org/10.1016/j.ijbiomac.2012.08.016] [PMID: 22947453]
[88]
Singh SK, Kosuru R, Dewangan HK, Singh S. An overview on asenapine maleate: PK-PD, preclinical and clinical update. Pharmasociety 2015; 11: 110-5.
[89]
Foroozandeh P, Aziz AA. Insight into cellular uptake and intracellular trafficking of nanoparticles. Nanoscale Res Lett 2018; 13(1): 339-47.
[http://dx.doi.org/10.1186/s11671-018-2728-6] [PMID: 30361809]
[90]
Dewangan HK, Tomar S. Nanovaccine for transdermal delivery. J Drug Del Sci Tech 2021; 102988.
[91]
Dewangan HK. Rational application of nanoadjuvant for mucosal vaccine delivery system. Immunol Methods 2020; 112791-807.
[92]
Commisso C, Davidson SM, Soydaner-Azeloglu RG, et al. Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells. Nature 2013; 497: 633.
[http://dx.doi.org/10.1038/nature12138]
[93]
Dewangan HKA. Review: Chitosan as natural versatile material for biomedical and diseases treatment. IJISET 2020; 7(11): 107-20.
[94]
Dewangan HK. Albumin as natural versatile drug carrier for various diseases treatment. Sustain Agric Res 2020; 43: 239-68.
[95]
Yadav D, Dewangan HK. PEGYLATION: An important approach for novel drug delivery system. J Biomater Sci Polym Ed 2020; 3: 1-15.
[PMID: 32942961]
[96]
Singh AV, Ansari MHD, Rosenkranz D, et al. Artificial intelligence and machine learning in computational nanotoxicology: Unlocking and empowering nanomedicine. Adv Healthcare Mater 2020; 9: 1-19.
[97]
Singh AV, Chandrasekar V, Janapareddy P, et al. Emerging application of nanorobotics and artificial intelligence to cross the BBB: Advances in design, controlled maneuvering, and targeting of the barriers. ACS Chem Neurosci 2021; 12(11): 1835-53.
[http://dx.doi.org/10.1021/acschemneuro.1c00087] [PMID: 34008957]
[98]
Singh AV, Jahnke T, Wang S, et al. Anisotropic gold nanostructures: Optimization via in silico modeling for hyperthermia. ACS Appl Nano Mater 2018; 1(11): 6205-16.
[http://dx.doi.org/10.1021/acsanm.8b01406]
[99]
Dewangan HK. Different approaches for nanovaccine formulation and characterization. Mater Sci Eng 2021; 1116(1): 012042.
[100]
Dewangan HK, Singh S, Mishra R, Dube RK. A review on application of nanoadjuvant as delivery system. IJAP 2020; 12(4): 24-33.
[http://dx.doi.org/10.22159/ijap.2020v12i4.36856]

Rights & Permissions Print Cite
Article Metrics
14
1
© 2024 Bentham Science Publishers | Privacy Policy